TY  - JOUR
AU  - Milosevic, Zorica
AU  - Tanić, Nikola
AU  - Banković, Jasna Z.
AU  - Stankovic, Tijana
AU  - Buta, Marko
AU  - Lavrnic, Dragana
AU  - Milovanovic, Zorka
AU  - Pupic, Gordana
AU  - Stojković Burić, Sonja
AU  - Milinkovic, Vedrana
AU  - Ito, Yasuhiro
AU  - Džodić, Radan R.
PY  - 2014
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2290
AB  - Multiple cancers represent 2.42\% of all human cancers and are mainly
   double or triple cancers. Many possible causes of multiple malignancies
   have been reported such as genetic alterations, exposure to anti-cancer
   chemotherapy, radiotherapy, immunosuppressive therapy and reduced
   immunologic response. We report a female patient with multiple sclerosis
   and quadruple cancers of different embryological origin. Patient was
   diagnosed with stage III (T3, N1a, MO) medullary thyroid carcinoma
   (MTC), multicentric micropapillary thyroid carcinoma, scapular and
   lumbar melanomas (Clark II, Breslow II), and lobular invasive breast
   carcinoma (T1a, NO, MO). All tumors present in our patient except
   micropapillary thyroid carcinomas were investigated for gene alterations
   known to have a key role in cancer promotion and progression. Tumor
   samples were screened for the p16 alterations (loss of heterozygosity
   and homozygous deletions), loss of heterozygosity of PTEN, p53
   alterations (mutational status and loss of heterozygosity) and
   mutational status of RET, HRAS and KRAS. Each type of tumor investigated
   had specific pattern of analyzed genetic alterations. The most prominent
   genetic changes were mutual alterations in PTEN and p53 tumor
   suppressors present in breast cancer and two melanomas. These
   co-alterations could be crucial for promoting development of multiple
   malignancies. Moreover the insertion in 4th codon of HRAS gene was
   common for all tumor types investigated. It represents frameshift
   mutation introducing stop codon at position 5 which prevents synthesis
   of a full-length protein. Since the inactivated RAS enhances sensitivity
   to tamoxifen and radiotherapy this genetic alteration could be
   considered as a good prognostic factor for this patient.
T2  - International Journal of Clinical and Experimental Pathology
T1  - Genetic alterations in quadruple malignancies of a patient with multiple
 sclerosis: their role in malignancy development and response to therapy
IS  - 4
VL  - 7
SP  - 1826
EP  - 1833
UR  - https://hdl.handle.net/21.15107/rcub_ibiss_2290
ER  - 

@article{
author = "Milosevic, Zorica and Tanić, Nikola and Banković, Jasna Z. and Stankovic, Tijana and Buta, Marko and Lavrnic, Dragana and Milovanovic, Zorka and Pupic, Gordana and Stojković Burić, Sonja and Milinkovic, Vedrana and Ito, Yasuhiro and Džodić, Radan R.",
year = "2014",
abstract = "Multiple cancers represent 2.42\% of all human cancers and are mainly
   double or triple cancers. Many possible causes of multiple malignancies
   have been reported such as genetic alterations, exposure to anti-cancer
   chemotherapy, radiotherapy, immunosuppressive therapy and reduced
   immunologic response. We report a female patient with multiple sclerosis
   and quadruple cancers of different embryological origin. Patient was
   diagnosed with stage III (T3, N1a, MO) medullary thyroid carcinoma
   (MTC), multicentric micropapillary thyroid carcinoma, scapular and
   lumbar melanomas (Clark II, Breslow II), and lobular invasive breast
   carcinoma (T1a, NO, MO). All tumors present in our patient except
   micropapillary thyroid carcinomas were investigated for gene alterations
   known to have a key role in cancer promotion and progression. Tumor
   samples were screened for the p16 alterations (loss of heterozygosity
   and homozygous deletions), loss of heterozygosity of PTEN, p53
   alterations (mutational status and loss of heterozygosity) and
   mutational status of RET, HRAS and KRAS. Each type of tumor investigated
   had specific pattern of analyzed genetic alterations. The most prominent
   genetic changes were mutual alterations in PTEN and p53 tumor
   suppressors present in breast cancer and two melanomas. These
   co-alterations could be crucial for promoting development of multiple
   malignancies. Moreover the insertion in 4th codon of HRAS gene was
   common for all tumor types investigated. It represents frameshift
   mutation introducing stop codon at position 5 which prevents synthesis
   of a full-length protein. Since the inactivated RAS enhances sensitivity
   to tamoxifen and radiotherapy this genetic alteration could be
   considered as a good prognostic factor for this patient.",
journal = "International Journal of Clinical and Experimental Pathology",
title = "Genetic alterations in quadruple malignancies of a patient with multiple
 sclerosis: their role in malignancy development and response to therapy",
number = "4",
volume = "7",
pages = "1826-1833",
url = "https://hdl.handle.net/21.15107/rcub_ibiss_2290"
}

Milosevic, Z., Tanić, N., Banković, J. Z., Stankovic, T., Buta, M., Lavrnic, D., Milovanovic, Z., Pupic, G., Stojković Burić, S., Milinkovic, V., Ito, Y.,& Džodić, R. R.. (2014). Genetic alterations in quadruple malignancies of a patient with multiple
 sclerosis: their role in malignancy development and response to therapy. in International Journal of Clinical and Experimental Pathology, 7(4), 1826-1833.
https://hdl.handle.net/21.15107/rcub_ibiss_2290

Milosevic Z, Tanić N, Banković JZ, Stankovic T, Buta M, Lavrnic D, Milovanovic Z, Pupic G, Stojković Burić S, Milinkovic V, Ito Y, Džodić RR. Genetic alterations in quadruple malignancies of a patient with multiple
 sclerosis: their role in malignancy development and response to therapy. in International Journal of Clinical and Experimental Pathology. 2014;7(4):1826-1833.
https://hdl.handle.net/21.15107/rcub_ibiss_2290 .

Milosevic, Zorica, Tanić, Nikola, Banković, Jasna Z., Stankovic, Tijana, Buta, Marko, Lavrnic, Dragana, Milovanovic, Zorka, Pupic, Gordana, Stojković Burić, Sonja, Milinkovic, Vedrana, Ito, Yasuhiro, Džodić, Radan R., "Genetic alterations in quadruple malignancies of a patient with multiple
 sclerosis: their role in malignancy development and response to therapy" in International Journal of Clinical and Experimental Pathology, 7, no. 4 (2014):1826-1833,
https://hdl.handle.net/21.15107/rcub_ibiss_2290 .